| 40.19 Delayed Data As of Aug 16 |  +0.23 / +0.58%Today’s Change | 36.41 Today|||52-Week Range 42.47 | +5.18% Year-to-Date |
| Better Buy: Eli Lilly vs. GlaxoSmithKline 7:28am / MotleyFool.com - Paid Partner Content | AnaptysBio Prepares for a Potential Gear Shift Aug 10 / MotleyFool.com - Paid Partner Content |
| Ionis Pharmaceuticals Looks to Partners to Pay the Bills Aug 14 / MotleyFool.com - Paid Partner Content | Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat Aug 09 / Zacks.com - Paid Partner Content |
| Should Value Investors Consider GlaxoSmithKline (GSK) Stock? Aug 13 / Zacks.com - Paid Partner Content |
| Previous close | 39.96 |
| Today’s open | 40.21 |
| Day’s range | 40.15 - 40.39 |
| Volume | 1,367,110 |
| Average volume (3 months) | 2,409,965 |
| Market cap | $96.5B |
| Earnings growth (last year) | +143.10% |
| Earnings growth (this year) | -7.36% |
| Earnings growth (next 5 years) | +4.00% |
| Revenue growth (last year) | +5.72% |
| P/E ratio | 18.6 |
| Price/Sales | 2.31 |
| Price/Book | 17.14 |
| Today’s change | Today’s % change | |
|---|---|---|
| SNYSanofi | +0.37 | +0.89% |
| ABBVAbbVie | +1.45 | +2.30% |
| LLYEli Lilly and Co | +0.29 | +0.26% |
| NVONovo Nordisk | +1.37 | +2.72% |
| Next reporting date | October 23, 2019 |
| EPS forecast (this quarter) | $0.78 |
| Annual revenue (last year) | $41.1B |
| Annual profit (last year) | $4.8B |
| Net profit margin | 11.75% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer & Executive Director Emma Walmsley |
Chief Financial Officer & Executive Director Iain James Mackay |
Corporate headquarters Brentford, Greater London |
